Atrial fibrillation and diabetes mellitus. Correlation, co-existence, and coagulation therapy

Herz

Volumn 37, Issue 3, 2012, Pages 258-263

  Stratmann, B ^a   Tschope D ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Diabetes mellitus; Risk factor; Risk score

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; C REACTIVE PROTEIN; DABIGATRAN; EDOXABAN; HIGH DENSITY LIPOPROTEIN; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FRAMINGHAM RISK SCORE; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; DIABETES COMPLICATIONS; GERMANY; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84863101800     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3600-6     Document Type: Article

References (48)

1. Huxley R, Barzi F, Woodward M (2006) Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332: 73-78
2. Aviles RJ, Martin DO, Apperson-Hansen C et al (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108: 3006-3010 (Pubitemid 37553570)
3. Psaty BM, Manolio TA, Kuller LH et al (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96: 2455-2461 (Pubitemid 27425856)
4. Aksnes TA, Schmieder RE, Kjeldsen SE et al (2008) Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE trial). Am J Cardiol 101: 634-638 (Pubitemid 351625088)
5. Nichols GA, Reinier K, Chugh SS (2009) Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 32: 1851-1856
6. Benjamin EJ, Levy D, Vaziri SM et al (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271: 840-844
7. Johansen OE, Brustad E, Enger S et al (2008) Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects. Cardiovasc Diabetol 7: 28
8. Movahed MR, Hashemzadeh M, Jamal MM (2005) Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105: 315-318 (Pubitemid 41605083)
9. Stewart S, Hart CL, Hole DJ et al (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113: 359-364 (Pubitemid 35223606)
10. Watanabe H, Tanabe N, Watanabe T et al (2008) Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 117: 1255-1260 (Pubitemid 351365676)
11. Iguchi Y, Kimura K, Aoki J et al (2008) Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 72: 909-913 (Pubitemid 351879910)
12. Krahn AD, Manfreda J, Tate RB et al (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98: 476-484
13. Frost L, Hune LJ, Vestergaard P (2005) Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 118: 489-495 (Pubitemid 40615472)
14. Ostgren CJ, Merlo J, Rastam L et al (2004) Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 6: 367-374 (Pubitemid 39172859)
15. Ruigomez A, Johansson S, Wallander MA et al (2002) Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 55: 358-363 (Pubitemid 34245363)
16. Ruigomez A, Johansson S, Wallander MA et al (2005) Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc Disord 5: 20
17. Wilhelmsen L, Rosengren A, Lappas G (2001) Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med 250: 382-389 (Pubitemid 32989592)
18. Jeong JH (2005) Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 20: 26-30
19. Smith JG, Platonov PG, Hedblad B et al (2010) Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 25: 95-102
20. Zhou Z, Hu D (2008) An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 18: 209-216
21. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12: 1360-1420
22. Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 651-745
23. Benjamin EJ, Chen PS, Bild DE et al (2009) Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 119: 606-618
24. Watanabe H, Tanabe N, Yagihara N et al (2011) Association between lipid profile and risk of atrial fibrillation. Circ J 75: 2767-2774
25. Du X, Ninomiya T, Galan B de et al (2009) Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30: 1128-1135
26. Huxley RR, Alonso A, Lopez FL et al (2012) Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 98: 133-138
27. Dublin S, Glazer NL, Smith NL et al (2010) Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 25: 853-858
28. Bluher M, Fasshauer M, Tonjes A et al (2005) Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113: 534-537 (Pubitemid 41585991)
29. Rutter MK, Parise H, Benjamin EJ et al (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107: 448-454 (Pubitemid 36158048)
30. Otake H, Suzuki H, Honda T et al (2009) Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J 50: 627-641
31. Gami AS, Hodge DO, Herges RM et al (2007) Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 49: 565-571 (Pubitemid 46177437)
32. Velagaleti RS, Massaro J, Vasan RS et al (2009) Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation 120: 2345-2351
33. Schillaci G, Vaudo G, Reboldi G et al (2001) High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 19: 2265-2270 (Pubitemid 33135250)
34. Chung MK, Martin DO, Sprecher D et al (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104: 2886-2891 (Pubitemid 33139098)
35. Mihm MJ, Yu F, Carnes CA et al (2001) Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104: 174-180 (Pubitemid 32655834)
36. Annoura M, Ogawa M, Kumagai K et al (1999) Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology 92: 21-27 (Pubitemid 30055079)
37. Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137: 263-272
38. Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138: 1093-1100
39. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983-988
40. Hart RG, Pearce LA, Rothbart RM et al (2000) Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 35: 183-187 (Pubitemid 30061278)
41. Kreuzer J (2011) Update on anti-coagulation in atrial fibrillation. QJM 104: 747-760
42. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151
43. Ezekowitz MD, Connolly S, Parekh A et al (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157: 805-810, 810 e801-802
44. Connolly SJ, Ezekowitz MD, Yusuf S et al (2010) Newly identified events in the RE-LY trial. N Engl J Med 363: 1875-1876
45. Oldgren J, Alings M, Darius H et al (2011) Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS 2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 155: 660-667, W204
46. Investigators RAs (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159: 340-347 e341
47. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891
48. Huxley RR, Filion KB, Konety S et al (2011) Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108: 56-62